NASDAQ: ALVOAlvotech Stock
$9.12-0.02 (-0.22%)
Updated Jun 30, 2025
ALVO Price
$9.12
Fair Value Price
N/A
Market Cap
$2.75B
52 Week Low
$7.35
52 Week High
$13.70
P/E
22.24x
P/B
-9.11x
P/S
4.96x
PEG
0.63x
Dividend Yield
N/A
Revenue
$587.89M
Earnings
$96.55M
Gross Margin
60.7%
Operating Margin
43.49%
Profit Margin
16.4%
Debt to Equity
-5.12
Operating Cash Flow
-$96M
Beta
0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALVO Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALVO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ALVO
Ranked#19 of 60
Ranked#19 of 60
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.54 | A | |
| $3.35 | A | |
| $8.09 | A |
Be the first to know about important ALVO news, forecast changes, insider trades & much more!
ALVO News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALVO ($9.12) is trading above its intrinsic value of $7.46, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALVO is good value based on its earnings relative to its share price (22.24x), compared to the US market average (32.47x)
P/E vs Market Valuation
ALVO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ALVO due diligence checks available for Premium users.
Valuation
ALVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.24x
Industry
-31.27x
Market
32.47x
ALVO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ALVO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ALVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.11x
Industry
2.23x
ALVO price to earnings growth (PEG)
For valuing profitable companies with growth potential
ALVO is good value based... subscribe to Premium to read more.
PEG Value Valuation
ALVO's financial health
Profit margin
Revenue
$132.8M
Net Income
$109.7M
Profit Margin
82.6%
ALVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$1.5B
Debt to equity
-5.12
ALVO's short-term assets ($458.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALVO's long-term liabilities ($1.28B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$17.4M
Investing
-$20.4M
Financing
-$5.8M
ALVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALVO vs Pharmaceutical Stocks
Alvotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.